Trade Mark Journal No.2026/014 3 April 2026
WO0000001893723 (42)
Office of origin: United States of America
Date of International Registration:15 July 2025
Date of designation in the UK:
15 July 2025
International priority date claimed: 17 January 2025
(United States of America)
(99007063)
- Class 42
- Drug discovery and development; product research and development; scientific research and development services; pharmaceutical research and development; development of pharmaceutical preparations and drugs; identification, production and development of therapeutics, cell therapies, bioengineered cells and proteins for the treatment and prevention of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; identification, production and development of cell therapy solutions, namely protein design and custom cell programming; scientific, medical, biotechnology, biomedical, and pharmaceutical research, development, testing and analysis services; protein engineering and design services; cell programming services; research, development, discovery and consulting services in the fields of cell therapy and immuno-oncology; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical and clinical research and development services; scientific research and development, scientific laboratory services, medical and scientific research, biotechnology research and synthetic biology research, all of the foregoing relating to human beings; development of pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; development of pharmaceutical preparations and drugs in the field of gene therapy; medical research laboratory services, namely, tissue material processing and analysis in the field of cell therapy and immuno-oncology; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services; engineering of biological cells, cellular targets, proteins, and antibodies for others; providing of scientific and research information about medical, biotechnology, biomedical, and pharmaceutical fields for the prevention and treatment of human diseases, disorders and conditions via a website; provision of drug discovery, development and testing information; providing of scientific and research information in the scientific, medical, biotechnology, biomedical, and pharmaceutical fields for the prevention and treatment of human diseases, disorders and conditions via a website; providing of scientific and research information about prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of the prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders via a website; provision of scientific and research information about prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of cell therapy and immuno-oncology; providing of scientific and research information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of cell therapy and immuno-oncology via a website; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing of scientific and research information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of pharmaceuticals and clinical trials via a website; provision of scientific and medical research information in the fields of biotechnology, biomedical, and pharmaceuticals; providing information relating to the diagnostic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of human diseases, disorders and conditions; provision of scientific and research information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders.
Outpace Bio, Inc.
Representative: Bird & Bird LLP, 12 New Fetter Lane London EC4A 1JP UNITED KINGDOM